Literature DB >> 1315339

Detection of hepatitis C virus sequences in sera with controversial serology by nested polymerase chain reaction.

Y Lazizi1, E Elfassi, J Pillot.   

Abstract

The specificity of first-generation enzyme-linked immunosorbent assays (ELIAs) for antibody detection in individuals with hepatitis C virus (HCV) infection has been questioned in some pathological situations. We observed a surprisingly high prevalence of anti-HCV antibodies in alcoholic patients, and thus, false-positive reactions in anti-HCV tests were strongly suspected. The introduction of new epitopes, particularly a core protein, C22 (second-generation tests), seems to increase the sensitivity of anti-HCV detection. In order to study the specificity of the second-generation tests, 60 serum samples from alcoholic patients found to be positive by the first-generation anti-HCV ELISA (Ortho) were reexamined by a second-generation anti-HCV enzyme immunoassay (Abbott) and a recombinant immunoblot assay (RIBA II; Chiron). Fifteen serum samples gave contradictory results when they were tested by the two assays. We performed nested polymerase chain reactions (PCRs) to confirm that the discrepancies that we observed could be due to the presence of low levels of anti-HCV antibodies, which were detected by a more sensitive test, or to unspecific positive reactions. Nested PCR revealed the presence of HCV RNA sequences in all anti-HCV-positive sera or sera that were weakly positive by ELISA. Anti-HCV positive by RIBA II was always correlated with the presence of viral RNA in serum, but HCV RNA was detected in RIBA II-negative sera. These results indicate that the specificity of the second-generation tests is an important improvement but that an HCV infection can still persist without detectable antibodies. PCR remains the reference assay to clear up controversial serology results and to detect HCV infection in patients with no anti-HCV-detectable immune response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315339      PMCID: PMC265188          DOI: 10.1128/jcm.30.4.931-934.1992

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

Review 1.  The hepatitis C virus and its relationship to the clinical spectrum of NANB hepatitis.

Authors:  H J Alter
Journal:  J Gastroenterol Hepatol       Date:  1990       Impact factor: 4.029

2.  Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma.

Authors:  M Colombo; G Kuo; Q L Choo; M F Donato; E Del Ninno; M A Tommasini; N Dioguardi; M Houghton
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

3.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.

Authors:  R K Saiki; D H Gelfand; S Stoffel; S J Scharf; R Higuchi; G T Horn; K B Mullis; H A Erlich
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

4.  Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay.

Authors:  C L Van der Poel; H T Cuypers; H W Reesink; A J Weiner; S Quan; R Di Nello; J J Van Boven; I Winkel; D Mulder-Folkerts; P J Exel-Oehlers
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

5.  Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands.

Authors:  C L van der Poel; H W Reesink; P N Lelie; A Leentvaar-Kuypers; Q L Choo; G Kuo; M Houghton
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

6.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

7.  Structure and organization of the hepatitis C virus genome isolated from human carriers.

Authors:  A Takamizawa; C Mori; I Fuke; S Manabe; S Murakami; J Fujita; E Onishi; T Andoh; I Yoshida; H Okayama
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

8.  An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis.

Authors:  G Kuo; Q L Choo; H J Alter; G L Gitnick; A G Redeker; R H Purcell; T Miyamura; J L Dienstag; M J Alter; C E Stevens
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

9.  Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

Authors:  I G McFarlane; H M Smith; P J Johnson; G P Bray; D Vergani; R Williams
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

Review 10.  The liver and IgA: immunological, cell biological and clinical implications.

Authors:  W R Brown; T M Kloppel
Journal:  Hepatology       Date:  1989-05       Impact factor: 17.425

View more
  12 in total

1.  Evaluation of third-generation assays for detection of anti-hepatitis C virus (HCV) antibodies and comparison with presence of HCV RNA in blood donors reactive to c100-3 antigen.

Authors:  D Lavanchy; C Mayerat; B Morel; P Schneider; C Zufferey; J J Gonvers; A Pécoud; P C Frei
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

2.  Discordance between four second-generation enzyme immunoassay kits in anti-hepatitis C virus screening. The Study Group of the Laboratoires de Virologie des Centres Hospitaliers Universitaires français.

Authors:  Y Lazizi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

3.  Rapid diagnosis of Argentine hemorrhagic fever by reverse transcriptase PCR-based assay.

Authors:  M E Lozano; D Enría; J I Maiztegui; O Grau; V Romanowski
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

4.  Hepatitis C markers in hemodialysis patients.

Authors:  C S Huang; M S Ho; C S Yang; C L Lee; C A Tan
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

5.  Prevalence and significance of hepatitis C virus (HCV) viremia in HCV antibody-positive subjects from various populations.

Authors:  M François; F Dubois; D Brand; Y Bacq; C Guerois; C Mouchet; J Tichet; A Goudeau; F Barin
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

6.  Role of hepatitis C virus in chronic liver disease occurring after orthotopic liver transplantation.

Authors:  M Pastore; M Willems; C Cornu; J P Buts; R Reding; J de Ville de Goyet; J Rahier; J B Otte; S H Yap; E M Sokal
Journal:  Arch Dis Child       Date:  1995-05       Impact factor: 3.791

Review 7.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

8.  Follow-up study of acute hepatitis C.

Authors:  D Tan; S W Im; W W Peng; M H Ng
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA.

Authors:  J M Pawlotsky; A Fleury; V Choukroun; L Deforges; F Roudot-Thoraval; P Aumont; J Duval; D Dhumeaux
Journal:  J Clin Microbiol       Date:  1994-05       Impact factor: 5.948

10.  Hepatitis C virus (HCV)-specific in vitro antibody secretion by peripheral blood lymphocytes: correlation with progression of disease and HCV RNA in HCV antibody-positive patients.

Authors:  J Ducos; A M Bianchi-Mondain; M Francois; M Boisset; J P Vendrell; F Barin; A Serre; D Larrey
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.